SCHEMBL3531950

SCHEMBL3531950

COc1c(Cl)cccc1CC#N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 1/20 0.40
CACNG8 Q8WXS5 1/20 0.40
MAPT P10636 4/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX12 P18054 1/20 0.38
CYP2C19 P33261 1/20 0.38
P2RX7 Q99572 2/20 0.36
KDM4E B2RXH2 2/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
PKM P14618 1/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
PNMT P11086 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9080677 0.87 ALDH1A1 (0.40) GRIA1CACNG8KDM4ERAB9ANPC1
SCHEMBL11125167 0.83 SLC6A2 (0.47) MAPTMEN1KMT2AP2RX7L3MBTL1
SCHEMBL11195030 0.82 ALDH1A1 (0.41) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL11125781 0.82 PRMT3 (0.40) GRIA1CACNG8MAPTMEN1KMT2A
SCHEMBL4160051 0.80 SMN1; SMN2 (0.46) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL27725691 0.79 SLC6A2 (0.40) MAPTMEN1KMT2AP2RX7KDM4E
SCHEMBL27746446 0.79 MEN1 (0.38) MEN1KMT2ACYP1A2ALDH1A1HPGD
SCHEMBL31347547 0.79 DHFR (0.36) GRIA1CACNG8MAPTMEN1KMT2A
SCHEMBL11239298 0.77 PNMT (0.39) MAPTMEN1KMT2AP2RX7KDM4E
SCHEMBL10978584 0.77 GABRA1 (0.41) MAPTMEN1KMT2ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2888259-B1 DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE NOVARTIS AG (CH) 2018-03-07 EP disclosed
US-20170305903-A1 DIAZEPINONE DERIVATIVES NOVARTIS AG (CH) 2017-10-26 US disclosed
US-9650377-B2 Diazepinone derivatives NOVARTIS AG (CH) 2017-05-16 US disclosed
CN-104520298-B For treating two azepines ketone derivatives of fragile X syndrome, parkinson disease or reflux disease 诺华股份有限公司 2016-10-19 CN disclosed
US-20160159795-A1 DIAZEPINONE DERIVATIVES NOVARTIS AG (CH) 2016-06-09 US disclosed
CN-105611923-A Sodium channel modulators for the treatment of pain and diabetes CHROMOCELL CORP 2016-05-25 CN disclosed
US-9284331-B2 Diazepinone derivatives NOVARTIS AG (CH) 2016-03-15 US disclosed
EP-2888259-A1 DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE Novartis AG (CH) 2015-07-01 EP disclosed
US-20140357625-A1 DIAZEPINONE DERIVATIVES NOVARTIS AG (CH) 2014-12-04 US disclosed
US-8853203-B2 Diazepinone derivatives NOVARTIS AG (CH) 2014-10-07 US disclosed
EP-1786823-A1 ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS Bayer Schering Pharma Aktiengesellschaft (DE) 2007-05-23 EP disclosed
EP-1670458-B1 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS SCHERING AG (DE) 2006-12-20 EP disclosed
US-20060084652-A1 Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2006-04-20 US disclosed
EP-1638945-A1 HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS Schering Aktiengesellschaft (DE) 2006-03-29 EP disclosed
WO-2006027236-A1 ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-03-16 WO disclosed
US-20050272823-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-12-08 US disclosed
US-20050209324-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-09-22 US disclosed
US-20050171109-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-08-04 US disclosed
US-20050090559-A1 Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2005-04-28 US disclosed
WO-2005003098-A1 HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090559-A1 Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents IL1B, NFKBIA, BBOX1 GRIA1 2217/4885CACNG8 2509/4885MAPT 2912/4885
US-20060084652-A1 Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents PTGES, PTGS1, PTGES2 GRIA1 2700/4885CACNG8 3924/4885MAPT 2270/4885
US-20160159795-A1 DIAZEPINONE DERIVATIVES ADRB1, ADRB2, BRD4 GRIA1 57/4885CACNG8 2115/4885MAPT 1174/4885
US-20050171109-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents TNF, DHPS, PTGES GRIA1 3266/4885CACNG8 3385/4885MAPT 672/4885
US-20050272823-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents DHPS, TNF, PTGES GRIA1 2837/4885CACNG8 3758/4885MAPT 964/4885
US-20050209324-A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents TNF, DHPS, PTGES GRIA1 3266/4885CACNG8 3385/4885MAPT 672/4885
US-20170305903-A1 DIAZEPINONE DERIVATIVES ADRB1, ADRB2, BRD4 GRIA1 57/4885CACNG8 2115/4885MAPT 1174/4885
US-20140357625-A1 DIAZEPINONE DERIVATIVES ADRB1, ADRB2, BRD4 GRIA1 57/4885CACNG8 2115/4885MAPT 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.